Intravitreal Methotrexate and Rituximab for Intraocular Lymphoma

Patients with intraocular lymphoma were treated with intravitreal methotrexate and rituximab injections as described by Yeh and Wilson [22 (link)].

Free full text: Click here

Kuitunen H.K., Rönkä A.L., Sonkajärvi E.M., Isokangas J.M., Pyörälä M., Palosaari K.A., Jokimäki A.S., Partanen A.E., Littow H.J., Vakkala M.A., Jantunen E.J., Huttunen M.E., Marin K.J., Aromaa-Häyhä A.M., Auvinen P.K., Selander T., Puhakka I.K, & Kuittinen O.M. (2023). Blood–Brain Barrier Disruption (BBBD)-Based Immunochemotherapy for Primary Central Nervous System Lymphoma (PCNSL), Early Results of a Phase II Study. Cancers, 15(4), 1341.

Publication 2023

Intraocular lymphoma Methotrexate Patients Rituximab

Corresponding Organization : Oulu University Hospital

Other organizations : Kuopio University Hospital, University of Eastern Finland, North Karelia Central Hospital

Top 5 similar protocols

Variable analysis

independent variables

Intravitreal methotrexate injections
Intravitreal rituximab injections

dependent variables

Treatment outcomes for patients with intraocular lymphoma

control variables

Control variables not explicitly mentioned

controls

Positive and negative controls not explicitly mentioned

Annotations

This protocol is too short. Unable to provide accurate annotations

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!